TORONTO, Sept. 26, 2018 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN, OTCQB:
KHRNF, Frankfurt: A2JMZC), an
integrated medical cannabis company with its core operations
in Colombia, is pleased to announce its incorporation into the
Horizons Emerging Marijuana Growers Index ETF (NEO: HMRJ) (the
"ETF").
HMJR is an index (or passively managed) ETF, which seeks to
replicate, to the extent possible, the performance of the Emerging
Marijuana Growers Index, net of expenses. This index is designed to
provide exposure to the performance of a basket of primarily North
American publicly listed small-capitalization companies involved in
the cultivation, production and/or distribution of marijuana.
Publicly listed companies within the Index generally must have a
market capitalization greater than $50 million, but less
than $500 million for initial inclusion. HMJR is solely
invested in marijuana producers and distributors, and includes
exposure to companies listed outside of North America.
The ETF's full holdings can be viewed directly at the link
below;
https://www.horizonsetfs.com/horizons/media/ETFData/en-ca/HMJR/HorizonsHMJRHoldings.xls
About Horizons ETFs Management (Canada) Inc.
Horizons ETFs Management (Canada) Inc. is an innovative financial
services company and offers one of the largest suites of exchange
traded funds in Canada. The
Horizons ETFs product family includes a broadly diversified range
of solutions for investors of all experience levels to meet their
investment objectives in a variety of market conditions. Horizons
ETFs has more than $11 billion of
assets under management and 83 ETFs listed on major Canadian stock
exchanges. Horizons ETFs Management (Canada) Inc. is a member of the Mirae Asset
Global Investments Group.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. (TSXV: KHRN, OTCQB: KHRNF,
Frankfurt: A2JMZC)) ("Khiron" or
the "Company") is positioned to be the dominant integrated medical
cannabis company in Latin America. Khiron has core operations
in Colombia and is fully licensed in the country for the
cultivation, production, domestic distribution, and international
export of both tetrahydrocannabinol (THC) and cannabidiol (CBD)
medical cannabis. In May 2018, Khiron listed on the TSX
Venture Exchange, becoming the first Colombian based medical
cannabis company to trade on any exchange globally.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. Khiron is led by Co-founder and
Chief Executive Officer, Alvaro Torres, together with
an experienced executive team, and a knowledgeable Board of
Directors that includes former President
of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found
at www.khiron.ca.
Forward-Looking Statements
This press release may contain certain forward-looking
information and statements ("forward-looking information") within
the meaning of applicable Canadian securities legislation, that are
not based on historical fact, including without limitation
statements containing the words "believes", "anticipates", "plans",
"intends", "will", "should", "expects", "continue", "estimate",
"forecasts" and other similar expressions. Readers are cautioned to
not place undue reliance on forward-looking information. Actual
results and developments may differ materially from those
contemplated by these statements. Khiron undertakes no obligation
to comment analyses, expectations or statements made by
third-parties in respect of Khiron, its securities, or financial or
operating results (as applicable). Although Khiron believes that
the expectations reflected in forward-looking information in this
press release are reasonable, such forward-looking information has
been based on expectations, factors and assumptions concerning
future events which may prove to be inaccurate and are subject to
numerous risks and uncertainties, certain of which are beyond
Khiron's control, including the risk factors discussed in Khiron's
Filing Statement which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and are made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.